Print This Page
Email to a Friend
Prescribing Information
Patients and Caregivers
About ALOXI
How does ALOXI work?
What makes ALOXI different?
For discussion with your healthcare professional
Ingredients and administration
Understanding CINV
Types of CINV
Controlling CINV
Maintaining communication with your healthcare professional
What CINV medication may be right for you?
CINV likelihood from chemotherapies
What are the worst side effects
Perception vs Reality
Tips to Stay Strong
Online resources
Stay Strong Patient Support Program
Healthcare professionals
About Aloxi®
Binding Affinity
Half-Life & Metabolism
Indication
Recommended Dosage and Administration
Safety Profile
ALOXI® Phase III Clinical Trials
ALOXI® vs. Ondansetron in Moderately Emetogenic Chemotherapy
ALOXI® vs. Dolasetron in Moderately Emetogenic Chemotherapy
ALOXI® vs. Ondansetron and Dolasetron: Pooled Data
ALOXI® vs. Ondansetron and Dolasetron in Patients With Breast Cancer
ALOXI® vs. Ondansetron in Highly Emetogenic Chemotherapy
Nausea & Vomiting
Perception vs Reality
Acute Nausea & Vomiting
Delayed Nausea & Vomiting
Anticipatory Nausea & Vomiting
Emetogenicity Chart
Impact of Failed CINV Prevention
Impact on the Practice
ALOXI® Patient Information
Formulary Request Letter
Stay Strong Patient Support Program
ManageCINV.com
MGI Professional Services for Healthcare Providers
Request an MGI Territory Manager
Especially for nurses
Caring for your patients
Caring for yourself
ALOXI® Reimbursement
MGI Pharma Access Program (MAP)
FAQs
ALOXI® Reimbursement
Coding for ALOXI® and Related Services
Product and Administration Coding
Register for ALOXI® Reimbursement Updates
ALOXI® Reimbursement Forms
CMS 1450 (UB-92) Form
CMS 1500 Form
Letter of Medical Necessity
Appeal Letter - Medicare
ALOXI® FDA-Approval Letter
Carrier Advisory Committee Letter
Prescribing Product Information
Formulary Request Letter
Patient Assistance Program
ALOXI® Ordering Information